BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Iranian strikes on Israel injure 11 and set chemical plant ablaze - 2Sexual violence part of 'everyday life' in parts of Sudan, charity says
- 35 Advancement Developments in Biotechnology
- 4Palestine weekly wrap: Protests sweep West Bank after death penalty law
- 5April full moon 2026 dazzles as 'Pink Moon' lights up skies worldwide (photos)
- Astronauts on the ISS watched NASA's historic Artemis 2 launch from space
- Illustrations Gained from a Crosscountry Excursion
- Pick Your #1 Kind Of Treat
- Virtual reality opens doors for older people to build closer connections in real life
- Toddler given just 3 years to live after strange symptoms makes full recovery
- Chinese mega embassy could bring security advantages, says No 10
- Building Tough Connections: Individual Bits of knowledge on Association
- Investigate Business Mastercard Choices for Better Rewards and Rewards
- Chinese construction workers in Israel: 'I’d rather be bombed than live in poverty'
